一个现实世界的研究:ROS1-阳性高级NSCLC的治疗结果
Hanqi Yuan1, Zihua Zou1,2, Xuezhi Hao1
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Thoracic cancer
|May 12, 2025
概括
现实数据显示,ROS1测试转向NGS,而ROS1-TKI在中国NSCLC患者中使用量增加. 克里佐替尼证明了疗效,但中枢神经系统的进展需要更好的大脑保护策略.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- ROS1基因重组是非小细胞肺癌 (NSCLC) 的关键治疗标.
- 在中国人群中,关于ROS1诊断方法,治疗选择和结果的现实数据有限.
研究的目的:
- 分析中国ROS1阳性先进NSCLC的ROS1检测方法和治疗策略的趋势.
- 在现实世界中评估ROS1抑制剂的疗效和耐药性模式.
主要方法:
- 在2011年7月至2021年11月期间接受治疗的ROS1阳性晚期NSCLC患者的回顾性分析.
- 关于ROS1测试方法 (FISH与NGS),初始治疗选择 (TKI与化疗),疗效和耐药机制的文档.
主要成果:
- ROS1测试从FISH演变为NGS,在2019年后的NGS使用量大幅增加.
- 第一线ROS1-TKI使用显著增加,克里佐替尼是首选药物 (90%),实现了82.8%的客观反应率和18.7个月的PFS中位数.
- 中枢神经系统 (CNS) 的进展是常见的 (60%) 与crizotinib;复苏检查显示G2032R是最常见的二次突变 (48.3%的耐药病例).
结论:
- 诊断和治疗方面的进步,以及扩大保险覆盖范围,正在改善ROS1阳性NSCLC患者的治疗结果.
- 虽然crizotinib显示有效性,但需要改进中枢神经系统保护策略.
- 在临床实践中强调增加再活检率对于管理耐药性至关重要.
更多相关视频
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
3.9K
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
10.3K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K